Biohaven Pharmaceutical Holding Company Ltd.
Equities
BHVN
VGG111961055
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
54.69 USD | -4.09% |
|
-2.13% | -63.97% |
Mar. 04 | HC Wainwright Adjusts Biohaven's Price Target to $63 From $50, Maintains Buy Rating | MT |
Mar. 01 | TD Cowen Ups Price Target on Biohaven to $55 From $35, Keeps Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-63.97% | 541M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
-8.77% | 11.06B |
- Stock
- Equities
- Stock Biohaven Pharmaceutical Holding Company Ltd. - Nyse
- News Biohaven Pharmaceutical Holding Company Ltd.
- Biohaven Pharmaceutical Holding Company Reports Bigger Q2 Loss Despite Higher Revenue